Ceralasertib

Ceralasertib (AZD6738) is a small-molecule drug developed by AstraZeneca. Its target is ATR (the sponsor names ATR (Ataxia Telangiectasia and Rad3-related) kinase). The sponsor states: Ceralasertib is an oral small-molecule ATR kinase inhibitor, tested here in combination with the PD-L1 inhibitor durvalumab; the CT.gov record's exclusion criterion barring prior ATR inhibitor use is consistent with this. ClinicalTrials.gov describes the intervention as: Participants will receive oral tablet of ceralasertib as stated in arm description. It is the investigational product in 5 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05450692 (A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy), in non-small-cell lung cancer, melanoma and triple-negative breast cancer. The largest, NCT05450692, plans to enrol 594 participants (actual) with primary completion expected 2025-10-06. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.